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Abstract. Non-small cell lung cancer (NSCLC) accounts for 
~70% of all lung cancer-associated mortalities worldwide. The 
serine/threonine protein kinase tumor progression locus 2 
[TPL2/MAP3 kinase 8 (MAP3K8)] may impact oncogenic 
events; however the role of TPL2 in lung carcinogenesis 
remains unclear. The present study was focused on the poten-
tial prognostic role of TPL2 in 101 patients with early-stage 
NSCLC. Since TPL2 is a potential target of miR‑21, the 
association between TPL2 and miR‑21 expression was also 
examined. TPL2 and miR‑21 mRNA expression was quanti-
fied using reverse transcription quantitative polymerase chain 
reaction (RT-qPCR). TPL2 protein levels were evaluated by 
immunohistochemistry (IHC). The present study identified that 
the mRNA expression of TPL2 was low in 52/101 (51%) cases 
and high in 49/101 (49%) cases. IHC analysis of TPL2 protein 
expression often demonstrated identical mRNA results. No 
statistically significant associations were observed between the 
mRNA expression of TPL2 and the predominant clinicopatho-
logical characteristics of the patients with NSCLC, as well as 
identifying no association between TPL2 and miR‑21. TPL2 
mRNA expression was significantly higher in patients with 
NSCLC with good prognosis (disease-free interval P=0.009; 
overall survival P=0.024), when compared with those of poor 
prognosis. Focusing on the difference in mRNA expression 
of TPL2 among the adenocarcinomas in affected patients, 
TPL2 was more highly expressed in lepidic adenocarcinomas 
compared with in the other subtypes (P=0.012). The present 
study is the first examination, to the best of our knowledge, 
of TPL2 in early-stage NSCLC in relation to miR‑21, and 
in different adenocarcinoma subtypes. Future studies must 
clarify the mechanism by which TPL2 is involved in lung 
carcinogenesis due to its important translational implications.
Introduction
Although surgical intervention is effective for the majority of 
early-stage non-small cell lung cancer (NSCLC), ~20-30% 
of patients experience relapses (1). Therefore, the identifica-
tion of prognostic markers and novel therapeutic targets is 
of crucial importance. The serine/threonine protein kinase 
tumor progression locus 2 [TPL2/MAP3 kinase 8 (MAP3K8)] 
acts as an essential signal for the expression of pro‑inflamma-
tory mediators in several cell systems, including peripheral 
macrophages (2), adipocytes (3), hepatic stellate cells (4), 
airway epithelial cells (5) and glial cells (6). Inflammatory 
molecules have emerged as significant in the development 
of cancer, with roles in events leading to the formation, 
growth and metastasis of tumors. TPL2 has been suggested to 
enhance tumor growth and metastatic progression in distinct 
types of human cancer (7-9). Overexpression of TPL2 has 
been reported in human gastric/colon adenocarcinomas (10), 
large granular T-cell neoplasias (11) and breast cancer (12,13). 
However, a detailed evaluation of TPL2 expression and func-
tion in human malignancies and normal tissues remains to be 
performed, and the role of TPL2 in carcinogenesis remains 
unclear. TPL2 may stimulate oncogenic events, including the 
cellular response to therapy and immune control of cancer 
growth (14). However, in certain cases, TPL2 may function 
as a tumor suppressor (15). Little information regarding 
the prognostic role of TPL2 in the oncogenesis of NSCLC 
exists to assist with identifying those at high-risk of relapse 
following surgical resection.
Several previous studies have identified micro (mi) 
RNAs as critical regulators of immune responses, including 
inflammation (16,17). Mechanistically, miRNAs are small, 
non-coding RNA molecules that pair with partially comple-
mentary sequences in their target mRNAs and regulate their 
stability and/or translation. Extracellular signals, differentia-
tion and oncogenic transformation bring about alterations in 
the expression of miRNAs, allowing miRNAs to regulate 
these processes. Previous studies have suggested that miR‑21 
overexpression may be an independent negative prognostic 
factor in the overall survival of patients with NSCLC (18), 
and that miR‑21 targets numerous genes involved in cancer 
cell phenotypes (19). Using three miRNA target identifica-
tion programs (miRNAorg, MicroCosm Targets and PITA), 
TPL2 was identified among the potential targets of miR‑21. 
Therefore, the present study was based on the analysis of the 
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potential association between TPL2 and miR‑21 in cases of 
early-stage NSCLC.
Materials and methods
Patients. A total of 101 patients with NSCLC at peripheral 
stage I (T1N0M0) underwent surgical resection in the Unit 
of Thoracic Surgery in the Department of Surgical, Medical, 
Molecular Pathology and Critical Care at Pisa University (Pisa, 
Italy), and were retrospectively selected. Histological diag-
noses were formulated by two pathologists independently (G.F. 
and A.S.), in accordance with the World Health Organization 
classification (20,21). Clinicopathological characteristics were 
noted in all cases. Written informed consent was obtained 
from each patient for tissue collection and molecular analysis.
Target prediction. Alignment of miRNAs with the TPL2 
target gene was predicted using the microRNA target predic-
tion programs microRNA.org (Harvard Medical School, 
Boston, MA, USA), MicroCosm Targets 5.0 (The European 
Bioinformatics Institute) and PITA (Weizmann Institute of 
Science).
RNA isolation. Following standard deparaffinization and 
manual tumor macrodissection of the areas with preva-
lent adenocarcinomas, the miRNeasy formalin-fixed and 
paraffin-embedded (FFPE) kit (Qiagen GmbH, Hilden, 
Germany) was used to isolate total RNA, including miRNAs, 
from 5 µm sections of FFPE tissues, according to the manu-
facturer's protocol. A total of 600 ng of total RNA was used 
to synthesize cDNA using the RevertAid First Strand cDNA 
Synthesis kit (Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) in a reaction volume of 20 µl.
Expression of TPL2 mRNA and miR‑21 using the reverse 
transcription quantitative‑polymerase chain reaction 
(RT‑qPCR). Quantification of the mRNA expression of TPL2 
was performed in triplicate using the Rotor Gene SYBR Green 
PCR kit (Qiagen GmbH) on a Rotor Gene 6000 (Qiagen 
GmbH). The following primers used for RT-qPCR are as 
follows: TPL2, forward: 5'-TAATCCACAAGCAAGCAC 
CTC-3' and reverse: 5'-TGATTGGGGTTTCTCTCCAG-3'); 
β‑actin, forward: 5'-CCAACCGCGAGAAGATGA-3' and 
reverse: 5'-CCAGAGGCGTACAGGGATAG-3'. Specific 
TaqMan® MicroRNA assays (Applied Biosystems; Thermo 
Fisher Scientific, Inc.) were used to amplify miR‑21 and 
RNU6B, according to the manufacturer's protocol. In addition, 
the threshold cycle and baselines were determined in an iden-
tical manner. The expression was calculated by relative 
quantification using β-actin and RNU6B as reference controls 
for TPL2 and miR‑21, respectively. Fold expression changes 
were determined by the 2-∆∆Cq method (22) using a pool of 
12 non-cancerous tissues as a calibrator group. The analysis 
was performed using the DataAssist™ software (Applied 
Biosystems; Thermo Fisher Scientific, Inc.).
Protein expression of TPL2. The protein expression of TPL2 
was assessed in FFPE tissue samples using immuno-
histochemistry (IHC). The Cot (M-20) anti-TPL2 rabbit 
polyclonal antibody (dilution, 1:50; cat. no. sc-720, Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA) was incubated at 37˚C 
for 36 min to detect the protein. The avidin-biotin peroxi-
dase method was used by developing the immunoreaction 
with diaminobenzidine. Simultaneous staining of a known 
TPL2-positive case was used as a positive control. Incubation 
of parallel slides omitting the first antibody was performed as 
a negative control. The number of TPL2 immunoreactive cells 
was determined by scoring a minimum of five high‑power 
fields (magnification, x40) and counting the number of immu-
noreactive cells out of the total epithelial cells analyzed in 
each field of view.
A proportion score (PS) was assigned by representing 
the estimated proportion of positively stained cells, and was 
divided into three groups: negative (score 0), 1-60% (score 1) 
and >60% (score 2). An intensity score (IS) was also assigned 
and divided into four classes: None (score 0), weak (score 1), 
intermediate (score 2) and strong (score 3). A total score was 
obtained from the sum of the PS and IS, and was graded into 
two classes: High (4-5, with a higher expression of TPL2) and 
low (0-3, with a lower or negative TPL2 expression).
Statistical analysis. One-way analysis of variance and 
chi-squared tests were used to determine the association 
between the expression of TPL2, miR‑21 levels and the clini-
copathological parameters. Survival analyses were performed 
using the Kaplan-Meier method, along with the log-rank test 
and the Cox proportional hazard model. Statistical analyses 
were performed using the JMP10 software (SAS Institute, Inc., 
Cary, NC, USA). P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Patient characteristics. The present study was performed 
using 101 patients with early-stage NSCLC (71 males and 
30 females), including 54 patients with adenocarcinoma 
(ADC) and 47 patients with squamous cell carcinoma 
(SCC). Regarding their histological classification, different 
histological subtypes of ADC were identified: Acinar (19/54, 
35.2%), lepidic (18/54, 33.3%), mucinous (9/54, 16.7%), papil-
lary (6/54, 11.1%) and solid (2/54, 3.7%). The median age at 
diagnosis was 67 years (range, 49-81; mean, 67.03 years), and 
the median follow-up was 63 months (range, 6-161 months). In 
terms of tumor grade, five tumors were G1 phase, 71 tumors 
were G2 phase and 25 were G3 phase. Disease progression and 
mortality from lung cancer were observed in 27 patients with 
ADC (26.7%) and 20 with SCC (19.8%) of the 101 patients with 
NSCLC, respectively. The median progression-free survival 
and the overall survival were 54 months (95% CI: 6-161) and 
68 months (95% CI: 11-161), respectively. Regarding smoking 
habits of the entire patient group, there were 15 non-smokers, 
44 former smokers and 42 current smokers (Table I).
TPL2 expression and clinicopathological characteristics. 
TPL2 mRNA expression was quantified in 101 NSCLC 
tissues and in 12 non-cancerous tissues, and was normalized 
against the β‑actin housekeeping gene, using RT-qPCR. The 
samples were divided into high and low expression groups 
based on the median fold-change value (0.815 for TPL2). 
TPL2 mRNA expression was low in 52/101 (51%) cases and 
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high in 49/101 (49%) cases (data not shown). The present study 
determined whether TPL2 expression was correlated with the 
predominant clinicopathological characteristics. No statisti-
cally significant associations were observed between TPL2 
mRNA expression and any of the predominant clinicopatho-
logical characteristics of the patients with NSCLC (Table I). 
However, focusing on the difference in TPL2 levels among the 
different subtypes of the 54 adenocarcinomas, it was identi-
fied that TPL2 mRNA expression was high in 6/19 (31.6%) 
acinar, 13/18 (72.3%) lepidic, 5/9 (55.6%) mucinous, 3/6 (50%) 
papillary and 1/2 (50%) solid subtypes, with a significantly 
higher level in lepidic when compared with all other subtypes 
(Chi-squared test, P=0.012; data not shown).
Using the 2-level (high/low) immunohistochemical 
scoring system, TPL2 protein expression was low in 45/101 
(44%) and high in 56/101 (56%) cases (Fig. 1). Even if the 
correlation between the level of TPL2 mRNA and the score 
of its protein was not significant (chi‑squared test, P=0.36), 
samples with a low TPL2 protein score expression typically 
exhibited lower mRNA levels (2.33-fold change value ±1.55) 
when compared with samples with high TPL2 score (4.0±1.2). 
In addition, a high score for TPL2 protein was identified in the 
lepidic adenocarcinoma subtype (P=0.003), as aforementioned 
for TPL2 mRNA expression.
Target prediction and correlation between TPL2 and 
miR‑21 expression. Alignment of miRNAs with the TPL2 
target mRNA was predicted by the miRNA target predic-
tion programs miRBase, MicroCosm Targets and PITA. The 
present study identified the TPL2 gene as a potential target of 
miR‑21 (Fig. 2). Firstly, the patients with NSCLC were divided 
into miR‑21 high and low expression groups based on the 
median fold change values, which resulted as 1.7. Following 
this, the present study determined whether TPL2 expression 
was correlated with miR‑21 levels, but no statistically signifi-
cant associations were observed between groups (Chi-squared 
test, P=0.66).
Survival analysis. To evaluate the potential association 
between TPL2 expression and the prognosis of the patients 
with NSCLC, a survival analysis by the Kaplan-Meier 
method using the disease-free interval (DFI) and the overall 
post-operative survival (OS) as endpoints was performed. It 
was noted that the tumors with a high TPL2 mRNA expres-
sion demonstrated a significantly longer mean DFI and OS 
compared with the patients with low expression of this mRNA 
(P=0.009 and P=0.024, respectively; Fig. 3 and Table II). In 
the multivariate analysis, TPL2 mRNA expression continued 
to be a good prognostic factor for DFI and OS (P=0.0005 and 
P=0.005; Table II). Tumor grading, a classical prognostic factor, 
was also associated with the DFI in the univariate (P=0.0019) 
and multivariate analyses (P=0.0008; Table II), as well as with 
the OS (P=0.0009 and P=0.0002, respectively). No significant 
differences were identified for other demographics or clinical 
characteristics (Table II). Furthermore, the median DFI and 
OS were similar in examined patients with either low or high 
miR‑21 expression (data not shown).
Following this analysis, the survival difference between 
the histological cell types was investigated. No significant 
difference was observed between SCC and ADC (Table II). 
However, based on the difference of the TPL2 levels reported 
above, the NSCLCs were divided into three prognostic 
groups: Squamous cell carcinoma and the two predominant 
adenocarcinoma growth patterns (acinar and lepidic subtypes). 
The group with the most favorable prognosis was the lepidic 
predominant subtype, which was demonstrated earlier in the 
study to possess a higher level of TPL2, with a median DFI 
of 85 months and a median OS of 90 months. SCC and acinar 
ADC, both NSCLC tumors with lower TPL2 levels, presented 
a worse prognosis with a mean DFI of 53 and 68 months and 
with a mean OS of 65 and 68 months, respectively (P=0.02 and 
P=0.03; Fig. 4).
Discussion
TPL2 is involved in numerous intracellular signaling path-
ways, with a prominent role in the regulation of inflammatory 
signal transduction (2-6). TPL2 may be able to engage a 
plethora of signaling pathways and to act in concert with other 
kinases and signaling molecules. A major role of TPL2 is in 
the activation of the ERK/MAPK pathway through the direct 
phosphorylation of MEK, an extracellular signal-regulated 
kinase, which is a pro‑inflammatory mediator. Conversely, 
in certain disease models, TPL2 deficiency exacerbates the 
inflammatory response (23). The diverse and often contradic-
tory effects of TPL2 may be due to the utilization of different 
kinases and signal transduction pathways in different cell 
types. Similar contradictory data concerning the role of 
TPL2 in oncogenic signal transduction exist in the literature. 
Table I. Correlation between the mRNA expression of tumor 
progression locus 2 and the predominant clinicopathological 
characteristics of patients with early-stage non-small cell lung 
cancer.
 TPL2 expression
 ----------------------------------------
Characteristic Low % High % P-value
Age, years   0.368
  ≤67 24 (47.1) 27 (52.9)
  >67 28 (56.0) 22 (44.0)
Gender   0.809
  Male 36 (50.7) 35 (49.3)
  Female 16 (53.3) 14 (46.7)
Histology   0.471
  Adenocarcinoma 26 (48.1) 28 (51.9)
  Squamous cell carcinoma 26 (55.3) 21 (44.7)
Smoking history   0.512
  Never 6 (40.0) 9 (60.0)
  Former 25 (56.8) 19 (43.2)
  Current 21 (50.0) 21 (50.0)
Tumor grade   0.661
  G1 3 (60.0) 2 (54.5)
  G2 38 (53.5) 33 (46.5)
  G3 11 (44.0) 14 (56.0)
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Gkirtzimanaki et al (15) demonstrated a tumor suppressor 
function for TPL2 in lung cancer. However, in contrast, 
elevated levels of TPL2 have been reported in several tumor 
types (10-13). TPL2 inhibitors are currently in advanced phar-
maceutical development for the treatment of myeloma (24). 
The effects of inhibiting different MAP kinases may have 
different consequences in a cell-type-dependent manner, and 
therefore, any therapeutic use of kinase inhibitors must be 
carefully considered.
Considering these discrepancies, the aim of the present 
study was to elucidate the role of TPL2 in lung cancer, specifi-
cally in early-stage NSCLC. NSCLC accounts for ~70% of 
all lung cancer-associated mortalities worldwide (25). The 
current standard of care for stage I NSCLC is surgery; 
however, 20-30% of these early-stage patients will experience 
recurrence (1), reflecting the urgent requirement to develop 
adjunctive, specific markers that can aid in the prognosis of 
lung cancer. In the present report, it was demonstrated that 
low TPL2 mRNA levels correlated with reduced survival 
in TNM stage I lung cancer patients, suggesting loss of 
its expression was an early event in the development of the 
disease. Immunohistochemical analysis of TPL2 protein 
expression confirmed the corresponding mRNA results, even 
if not fully. There are presumably several reasons for a weak 
correlation between mRNA and protein levels, including 
mRNA post‑transcriptional modifications, translational effi-
ciency, miRNA actions and errors in both mRNA and protein 
measuring techniques. In addition, due to subcellular localiza-
tion, TPL2 protein abundance may not represent its biological 
activity.
It was later hypothesized that TPL2 may be correlated with 
miRNAs, which are small, non-coding RNAs that regulate 
target gene expression (26,27). Several miRNAs are aber-
rantly expressed in the majority of human cancer types (19). 
Oncogenes and tumor suppressor genes exert their activity, in 
part, by regulating the expression of specific miRNAs (28). 
Figure 1. Immunohistochemical staining of tumor progression locus 2 in adenocarcinomas with (A and B) lepidic prevalent pattern and (C and D) squamous 
cell carcinoma, with low level positive staining shown on the left and high level positive staining on the right (magnification, x10).
Figure 2. miR‑21 alignment with tumor progression locus 2 (MAP3K8) mRNA. The alignment of miR-21 with tumor progression locus 2 was determined 
using the miRBase target prediction program.
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miR‑21 has proven to be a useful prognostic indicator in 
numerous cancer types, including NSCLC (29,30). Using the 
miRNA target prediction programs miRBase, MicroCosm 
Targets and PITA, the present study identified TPL2 as a 
potential target of miR‑21. As a result, the study evaluated 
miR‑21 expression in early-stage NSCLC and its associa-
tion with TPL2 levels by combining miR‑21 expression with 
TPL2 levels. The present study is the first, to the best of our 
Table II. Factors associated with disease-free survival in patients with early-stage non-small cell lung cancer.
Characteristic Univariate analyses (P-value) Multivariate analyses (P-value)
Age (≤67 vs. >67 years) 0.7107 0.7141
Gender (male vs. female) 0.0866 0.4067
Histology (ADC vs. SCC) 0.1030 0.9908
Smoking (current/former vs. never) 0.5915 0.5477
Tumor grading (G1 vs. G2/G3) 0.0019 0.0008
TPL2 mRNA level (low vs. high) 0.0009 0.0005
ADC, adenocarcinoma; SCC, squamous cell carcinoma; TPL2, tumor progression locus 2.
Figure 3. Kaplan-Meier curves of patients with early-stage non-small cell lung cancer. Kaplan-Meier curves for the survival analysis of (A) DFI and (B) OS in 
101 patients with early-stage non-small cell lung cancer with high (blue line) or low (red line) TPL2 expression. High TPL2 mRNA expression demonstrated a 
significantly longer mean DFI and OS when compared to the patients with low expression of this mRNA (P=0.009 and P=0.024 vs. low TPL2 mRNA expres-
sion). TPL2, tumor progression locus 2; DFI, disease free interval; OS, overall survival.
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knowledge, to test the hypothesis that miR‑21 may cooperate 
with TPL2. It was revealed that TPL2 levels were not corre-
lated with miR‑21, suggesting no association between miR‑21 
and TPL2 in lung carcinogenesis. In addition, no difference in 
the disease prognosis was observed for miR‑21 in the present 
cases, as also previously reported by the authors (31). The 
prognostic role of this miRNA is controversial, whilst certain 
studies have demonstrated that miR‑21 overexpression is 
associated with poor NSCLC survival (18,32,33), other studies 
have indicated a converse or insignificant association (34,35). 
In view of the present results, the prognostic role of TPL2 is 
independent from the expression of miR‑21.
Furthermore, histological subtyping has been proposed 
as a potential screening tool to identify the patients with lung 
cancer at a high risk for recurrent disease and an unfavorable 
prognosis (36). In the comparisons between the patients with 
adenocarcinoma and squamous cell carcinoma, ADCs with 
a lepidic pattern exhibited significantly improved survival. 
Although this prognosis of lepidic adenocarcinoma (37-39), 
and the more aggressive course of the disease and poor prog-
nosis in the SCC histotype (40) have been well-documented, 
the finding of the lepidic ADC pattern correlation with high 
TPL2 expression has been not previously reported. Squamous 
cell lung carcinoma, even if clearly biologically different from 
the adenocarcinoma histotype, may behave as an adenocar-
cinoma arising from a non-terminal respiratory unit that is 
centrally originated, solid in morphology, poorly differenti-
ated and often necrotic (41).
TPL2 appears to have divergent roles in different cells 
and tissues, serving as an oncogene as well as a tumor 
suppressor gene. In addition, how TPL2 acts in carcino-
genesis remains to be elucidated. Gkirtzimanaki et al (15) 
hypothesized that TPL2 may lead to increased accumulation 
and activation of p53, resulting in an accelerated cell death 
and reduced malignant transformation. This hypothesis is 
corroborated by the good prognosis of lung cancer patients 
bearing tumors with elevated levels of TPL2, as it was iden-
tified in early‑stage NSCLCs. Downregulation of TPL2, as 
a result of a genetic or epigenetic alteration, including LOH, 
overexpression of miRNAs, or oncogenic RAS signaling, 
depending upon the histological subtype, may have an 
impact on the early stages of human lung disease similar to 
Figure 4. Kaplan-Meier curves of patients with SCC, acinar ADC and lepidic ADC subtype. Kaplan-Meier curves for the survival analysis of (A) DFI and 
(B) OS in patients with SCC (green line), acinar ADC (red line) and lepidic (blue line) ADC subtypes. The lepidic subtype possessed a higher median DFI and 
OS than the acinar subtype and SCC (P=0.02 and P=0.03 vs. SCC). DFI, disease free interval; OS, overall survival; SCC, squamous cell carcinoma.
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the effects of TPL2 ablation on lung cancer initiation in the 
mouse (15).
In conclusion, the present study is the first examination, to 
the best of our knowledge, of the association between TPL2 
and early-stage lung carcinogenesis, underscoring its tumor 
suppressor gene role. In the present analysis, miR‑21 expres-
sion did not impact on TPL2 expression. Future studies must 
involve an analysis of TPL2 in advanced lung cancer stages 
and its downstream signaling. In addition, studies must corre-
late findings with other miRNA expression profiles to clarify 
the mechanism by which TPL2 is involved in lung carcinogen-
esis, taking into consideration all histological subtypes, and 
any important translational implications.
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